Otsuka Pharmaceutical Co., Ltd. today announces it has received regulatory approval in Japan for a once-daily form in pediatric patients of Busulfex^® Injection 60 mg (generic name is busulfan). Busulfex is a conditioning regimen administered via intravenous drip to patients prior to undergoing hematopoietic stem cell transplantation.

Approval in Japan reflects the once-daily usage pattern for Busulfex in pediatric patients and adults in other countries around the world.